A study in renal predialysis and dialysis patients of the safety, tolerability, and immunogenicity of recombinant hepatitis B vaccine manufactured with a modified process.

Trial Profile

A study in renal predialysis and dialysis patients of the safety, tolerability, and immunogenicity of recombinant hepatitis B vaccine manufactured with a modified process.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 29 Oct 2009 Results were presented at IDSA 2009.
    • 03 Nov 2008 Trial identifier amended as reported by ClinicalTrials.gov.
    • 03 Nov 2008 Actual start date changed from Mar 2007 to Dec 2006 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top